Co-Diagnostics, Inc. (NASDAQ:CODX – Free Report)’s stock is going to reverse split before the market opens on Tuesday, November 24th. The 1-25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, November 23rd.
Co-Diagnostics Stock Down 21.3%
NASDAQ CODX traded down $0.04 during trading on Friday, reaching $0.13. 1,140,217 shares of the stock traded hands, compared to its average volume of 2,567,039. Co-Diagnostics has a fifty-two week low of $0.13 and a fifty-two week high of $13.54. The firm has a market cap of $1.36 million, a price-to-earnings ratio of -0.02 and a beta of 3.15. The stock’s 50-day moving average price is $0.72 and its 200 day moving average price is $2.03.
Co-Diagnostics (NASDAQ:CODX – Get Free Report) last posted its earnings results on Tuesday, November 10th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.25) by $0.24. The firm had revenue of $0.28 million during the quarter, compared to analysts’ expectations of $0.17 million. Co-Diagnostics had a negative return on equity of 322.92% and a negative net margin of 5,530.54%.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on CODX shares. Weiss Ratings cut Co-Diagnostics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, November 11th. Maxim Group raised shares of Co-Diagnostics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 18th. Finally, Wall Street Zen raised shares of Co-Diagnostics from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Co-Diagnostics currently has an average rating of “Hold” and an average target price of $45.00.
Check Out Our Latest Stock Analysis on Co-Diagnostics
Institutional Trading of Co-Diagnostics
An institutional investor recently bought a new position in Co-Diagnostics stock. Private Advisory Group LLC purchased a new position in shares of Co-Diagnostics, Inc. (NASDAQ:CODX – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 39,387 shares of the company’s stock, valued at approximately $122,000. Private Advisory Group LLC owned approximately 1.07% of Co-Diagnostics at the end of the most recent quarter. 14.99% of the stock is currently owned by institutional investors and hedge funds.
About Co-Diagnostics
Co-Diagnostics, Inc. is a molecular diagnostics company that develops technologies and tests for detecting infectious diseases. Based in Salt Lake City, Utah, the company’s work centers on its proprietary CoPrimer technology, used to design assays for polymerase chain reaction (PCR) testing. Its products include PCR-based diagnostic tests and related instruments, including the Co-Dx PCR platform. The company has developed tests for a range of infectious diseases, with product availability and regulatory status varying by market.
Featured Stories
- Five stocks we like better than Co-Diagnostics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
